Civitas Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

AC105 in Patients With Acute Traumatic Spinal Cord Injury

Phase 2

Terminated

Conditions: Acute Spinal Cord Injury

Interventions: Other: Placebo
Drug: AC105

First Posted Date: 2012-12-17

Last Posted Date: 2018-11-06

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 15

Registration Number: NCT01750684

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

Phase 3

Completed

Conditions: Spinal Cord Injury
Muscle Spasticity

Interventions: Drug: Fampridine-SR
Drug: Placebo

First Posted Date: 2012-09-12

Last Posted Date: 2017-08-25

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 204

Registration Number: NCT01683838

Locations: 🇺🇸
Craig Hospital, Englewood, Colorado, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

and more 27 locations

Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes

Phase 2

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: Placebo
Drug: Sinemet (carbidopa/levodopa)
Drug: CVT-301

First Posted Date: 2012-06-12

Last Posted Date: 2017-07-27

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 25

Registration Number: NCT01617135

Locations: 🇬🇧
Civitas Clinical Site #1, Glasgow, United Kingdom
🇬🇧
Civitas Clinical Site #2, Norwich, United Kingdom
🇬🇧
Civitas Clinical Site #3, Newcastle, United Kingdom

and more 4 locations

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: placebo/dalfampridine-ER
Drug: dalfampridine-ER/placebo

First Posted Date: 2012-05-25

Last Posted Date: 2016-01-22

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 83

Registration Number: NCT01605825

Locations: 🇺🇸
Acorda Site #006, Fairfield, Connecticut, United States
🇺🇸
Acorda Site #020, Great Falls, Montana, United States
🇺🇸
Acorda Site #023, Reno, Nevada, United States

and more 17 locations

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Completed

Conditions: Multiple Sclerosis

Interventions: Other: Withdrawal of dalfampridine-ER 10mg

First Posted Date: 2012-02-20

Last Posted Date: 2013-10-14

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 20

Registration Number: NCT01535664

Locations: 🇺🇸
OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Phase 1

Completed

Conditions: Cerebral Palsy (CP)

Interventions: Drug: dalfampridine-ER 10mg
Other: Placebo

First Posted Date: 2011-11-09

Last Posted Date: 2014-06-24

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 35

Registration Number: NCT01468350

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Rehabilitation Institute of Chicago, Chicago, Illinois, United States
🇺🇸
Detroit Clinical Research Center, Farmington Hills, Michigan, United States

and more 8 locations

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Diazepam

First Posted Date: 2011-08-16

Last Posted Date: 2017-03-29

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 31

Registration Number: NCT01417078

Locations: 🇺🇸
Barrow Neurology Clinics at St Joseph's Hospital, Phoenix, Arizona, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

and more 1 locations

Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

Phase 1

Terminated

Conditions: Spasticity Due to Cerebral Palsy

Interventions: Drug: Zanaflex Capsules

First Posted Date: 2011-07-29

Last Posted Date: 2013-06-17

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 10

Registration Number: NCT01405950

Locations: 🇺🇸
University of Louisville Department of Neurology dba Kentucky Neuroscience Research Health Care Outpatient Center (HCOC), Louisville, Kentucky, United States

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Dalfampridine-ER 10mg
Other: Placebo
Drug: Dalfampridine-ER 5mg

First Posted Date: 2011-04-04

Last Posted Date: 2013-09-05

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 430

Registration Number: NCT01328379

Locations: 🇺🇸
Texas Neurology, PA, Dallas, Texas, United States
🇺🇸
Swedish Neuroscience Institute, Seattle, Washington, United States
🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States

and more 66 locations

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Dalfampridine-ER

First Posted Date: 2011-03-16

Last Posted Date: 2012-11-07

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 42

Registration Number: NCT01316055

Locations: 🇺🇸
ACRI - Phase 1, Anaheim, California, United States
🇺🇸
MRA Clinical Research, South Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy